Gene-Edited Islets Show Promise, But Long-Term Questions Remain

Transplanting insulin-producing islet cells has been a goal in diabetes treatment for decades. The challenge has always been the same: the immune system attacks the new cells as foreign invaders. To prevent this, patients typically need to take immunosuppression drugs—medications that weaken the immune system overall, which can cause serious side effects.

Gene-edited hypoimmune islets offer a different path. Scientists modify the islet cells to hide from the immune system, theoretically allowing them to work without requiring powerful immunosuppression drugs. This could mean fewer drug side effects and better long-term health for transplant recipients.

Recent first-in-human trials provide the first real-world evidence that gene-edited islets can take hold and produce C-peptide (a marker of insulin production) without immunosuppression. Early immune monitoring at 12 weeks and follow-up data extending to 14 months are important proof-of-concept results.

However, 14 months is still relatively short in medical terms. The critical question researchers are now asking is whether this early success can translate into durable, long-term graft survival. Short-term immune evasion does not guarantee that these cells will remain protected for years or decades.

Scientists have identified several ways the immune system might eventually recognize and damage these gene-edited cells, even if they initially go undetected. One mechanism is indirect allorecognition—a process in which the immune system develops antibodies against transplanted cells through a delayed pathway. Non-HLA antibodies (antibodies against non-HLA proteins) could form gradually over months or years.

Other concerns include the persistence of autoreactive immune memory from the original Type 1 diabetes itself. If the immune system retains memory of attacking beta cells, it may eventually target the transplanted cells too. Additionally, gene-edited cells under metabolic stress might develop new surface markers that the immune system recognizes as abnormal. Finally, viral infections could trigger immune responses that damage the graft.

Based on current evidence and theory, researchers believe that gene-edited islets alone may not be sufficient for long-term success. Instead, a combination approach—pairing gene-edited islets with targeted immune-modulating treatments—may be necessary.

Potential adjunct therapies include teplizumab (which delays Type 1 diabetes onset), low-dose ATG (a type of immunosuppression), and tegoprubart. These agents could provide additional immune support without the high toxicity of traditional systemic immunosuppression. Metabolic support strategies may also help protect the transplanted cells.

Gene-edited hypoimmune islets represent a meaningful advance in transplant biology, moving the field away from a simple question—can these cells evade acute rejection?—to a harder one: can they stay protected and functional for the long term? Answering that question will require longer follow-up studies, careful immune monitoring, and possibly the integration of complementary treatments.

The stakes are high, and the early signs are hopeful. But the next chapters of this story will be written over years, not weeks.

Source: Expert opinion on biological therapy. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.